StockNews.com started coverage on shares of Evogene (NASDAQ:EVGN – Get Free Report) in a note issued to investors on Tuesday. The firm set a “sell” rating on the biotechnology company’s stock.
Separately, Lake Street Capital cut their price target on shares of Evogene from $30.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, August 23rd.
View Our Latest Stock Analysis on EVGN
Evogene Trading Up 19.9 %
Evogene (NASDAQ:EVGN – Get Free Report) last released its quarterly earnings results on Thursday, August 22nd. The biotechnology company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.94). Evogene had a negative return on equity of 72.33% and a negative net margin of 210.26%. The firm had revenue of $0.91 million for the quarter.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Evogene stock. BNP Paribas Financial Markets grew its stake in shares of Evogene Ltd. (NASDAQ:EVGN – Free Report) by 30.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 91,400 shares of the biotechnology company’s stock after acquiring an additional 21,500 shares during the period. BNP Paribas Financial Markets owned 0.22% of Evogene worth $69,000 at the end of the most recent reporting period. Institutional investors own 10.40% of the company’s stock.
About Evogene
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.
Read More
- Five stocks we like better than Evogene
- How to invest in marijuana stocks in 7 steps
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- Why Invest in High-Yield Dividend Stocks?
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- 10 Best Airline Stocks to Buy
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.